Login to Your Account



Nektar looks for sweet reward after pain med hits phase III endpoints

By Marie Powers
News Editor

Monday, March 20, 2017

Nektar Therapeutics Inc. looked to take the upper hand in partnering talks for NKTR-181, its mu-opioid agonist, after the molecule proved its mettle in a phase III study in more than 600 patients with moderate to severe chronic low back pain who were new to opioid therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription